Autologous and Allogeneic Transplantations for Chronic Lymphocytic Leukemia

[1]  W. Hiddemann,et al.  Treatment of advanced chronic lymphocytic leukemia by fludarabine , 1991, Annals of Hematology.

[2]  A. Rawstron,et al.  Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. , 2002, Blood.

[3]  A. Pileri,et al.  Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies. , 2002, Blood.

[4]  C. Solano,et al.  Allogeneic peripheral blood stem cell transplantation with reduced‐intensity conditioning: results of a prospective multicentre study , 2001, British journal of haematology.

[5]  P. Feugier,et al.  Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. , 2001, Blood.

[6]  W. Stock,et al.  Allogeneic and autologous transplantation for chronic lymphocytic leukemia , 2001, Leukemia.

[7]  J. Radich,et al.  Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. , 2001, Blood.

[8]  J. Esteve,et al.  Stem cell transplantation for chronic lymphocytic leukemia: different outcome after autologous and allogeneic transplantation and correlation with minimal residual disease status , 2001, Leukemia.

[9]  N. Schmitz,et al.  Reduced-intensity allogeneic stem cell transplantation as salvage treatment for patients with indolent lymphoma or CLL after failure of autologous SCT , 2000, Bone Marrow Transplantation.

[10]  S. Mackinnon.  Who may benefit from donor leucocyte infusions after allogeneic stem cell transplantation? , 2000, British journal of haematology.

[11]  M. Bishop,et al.  Outcome of allogeneic stem cell transplantation for B cell chronic lymphocytic leukemia , 2000, Bone Marrow Transplantation.

[12]  N. Young,et al.  Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. , 1999, Blood.

[13]  E. Montserrat,et al.  In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia. , 1999, Blood.

[14]  T J Hamblin,et al.  Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. , 1999, Blood.

[15]  N. Chiorazzi,et al.  Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. , 1999, Blood.

[16]  R. Foà,et al.  Clinical characteristics and outcome of young chronic lymphocytic leukemia patients: a single institution study of 204 cases. , 1999, Blood.

[17]  Peter Lichter,et al.  Chromosome aberrations in B-cell chronic lymphocytic leukemia: reassessment based on molecular cytogenetic analysis , 1999, Journal of Molecular Medicine.

[18]  P. Leoni,et al.  PBSC mobilization, collection and positive selection in patients with chronic lymphocytic leukemia , 1998, Bone Marrow Transplantation.

[19]  E J Freireich,et al.  Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. , 1998, Blood.

[20]  N. Ueno,et al.  Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  A. Gratwohl,et al.  Blood and marrow transplantation activity in Europe 1996 , 1998, Bone Marrow Transplantation.

[22]  N. Schmitz,et al.  leukaemia: a chance for cure? , 2022 .

[23]  A. Nagler,et al.  Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. , 1998, Blood.

[24]  N. Schmitz,et al.  Combined positive/negative selection for highly effective purging of PBPC grafts: towards clinical application in patients with B-CLL , 1997, Bone Marrow Transplantation.

[25]  B. Andersson,et al.  Allogeneic blood or marrow transplantation for chronic lymphocytic leukaemia: timing of transplantation and potential effect of fludarabine on acute graft‐versus‐host disease , 1997, British journal of haematology.

[26]  A. Gratwohl,et al.  Blood and marrow transplantation activity in Europe 1995 , 1997, Bone Marrow Transplantation.

[27]  J. Gribben,et al.  Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation. , 1996, Blood.

[28]  M. Andreeff,et al.  Graft-versus-leukemia effect after allogeneic bone marrow transplantation for chronic lymphocytic leukemia. , 1996, Bone marrow transplantation.

[29]  F. Bosch,et al.  Fludarabine in resistant or relapsing B-cell chronic lymphocytic leukemia: the Spanish Group experience. , 1996, Leukemia & lymphoma.

[30]  M. Hansen,et al.  Salvage therapy with fludarabine in patients with progressive B-chronic lymphocytic leukemia. , 1996, Leukemia & lymphoma.

[31]  S. Singhal,et al.  Clinical and hematologic response of chronic lymphocytic and prolymphocytic leukemia persisting after allogeneic bone marrow transplantation with the onset of acute graft-versus-host disease: possible role of graft-versus-leukemia. , 1996, Bone marrow transplantation.

[32]  E. Montserrat,et al.  HLA-Identical Sibling Bone Marrow Transplantation in Younger Patients with Chronic Lymphocytic Leukemia , 1996, Annals of Internal Medicine.

[33]  A. Saven,et al.  2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  M. Andreeff,et al.  A 3-day schedule of fludarabine in previously treated chronic lymphocytic leukemia. , 1995, Leukemia.

[35]  J. Binet.  Is the CHOP regimen a good treatment for advanced CLL? Results from two randomized clinical trials. French Cooperative Group on Chronic Lymphocytic Leukemia. , 1994, Leukemia & lymphoma.

[36]  E. Estey,et al.  Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. , 1993, Blood.

[37]  D. Neuberg,et al.  Autologous and allogeneic bone marrow transplantation for poor prognosis patients with B-cell chronic lymphocytic leukemia. , 1993, Blood.

[38]  G. Juliusson,et al.  Response to 2-chlorodeoxyadenosine in patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. , 1992, The New England journal of medicine.

[39]  R. Silver,et al.  A loading dose/continuous infusion schedule of fludarabine phosphate in chronic lymphocytic leukemia. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  M. Oken,et al.  Comparison of chlorambucil and prednisone versus cyclophosphamide, vincristine, and prednisone as initial treatment for chronic lymphocytic leukemia: long-term follow-up of an Eastern Cooperative Oncology Group randomized clinical trial. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  H. Kantarjian,et al.  Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  A. Saven,et al.  2-Chlorodeoxyadenosine Treatment of Refractory Chronic Lymphocytic Leukemia. , 1991, Leukemia & lymphoma.

[43]  E. Freireich,et al.  Long-Term Results of CAP Therapy in Chronic Lymphocytic Leukemia. , 1990, Leukemia & lymphoma.

[44]  R. Mick,et al.  Pentostatin in chronic lymphocytic leukemia: a phase II trial of Cancer and Leukemia group B. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  R. Peto.  REPRESENTATION OF THE PEOPLE? , 1988, The Lancet.

[46]  H. Kantarjian,et al.  Multiple agent chemotherapy (POACH) in previously treated and untreated patients with chronic lymphocytic leukemia. , 1988, Leukemia.

[47]  S. Molica,et al.  Prognostic value of the lymphocyte doubling time in chronic lymphocytic leukemia , 1987, Cancer.

[48]  A. Bartolucci,et al.  Treatment of chronic lymphocytic leukemia using chlorambucil and prednisone with or without cycle‐active consolidation chemotherapy .A southeastern cancer study group trial , 1986, Cancer.

[49]  Ciril Rozman,et al.  Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance , 1986, British journal of haematology.

[50]  E. Montserrat,et al.  Treatment of chronic lymphocytic leukemia in advanced stages. A randomized trial comparing chlorambucil plus prednisone versus cyclophosphamide, vincristine, and prednisone , 1985, Cancer.

[51]  H. Thaler,et al.  Combination chemotherapy of advanced chronic lymphocytic leukemia: the M-2 protocol (vincristine, BCNU, cyclophosphamide, melphalan, and prednisone). , 1982, Blood.

[52]  M. Gobbi,et al.  Staging of chronic lymphocytic leukemia. , 1982, Blood.

[53]  K. Rai,et al.  Comparison of daily versus intermittent chlorambucil and prednisone therapy in the treatment of patients with chronic lymphocytic leukemia. , 1977, Blood.

[54]  W. Knospe,et al.  Bi‐weekly chlorambucil treatment of chronic lymphocytic leukemia , 1974 .